United States

People: ACADIA Pharmaceuticals Inc (ACAD.O)

ACAD.O on Nasdaq

2 Dec 2016
Change (% chg)

$0.67 (+2.53%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Davis, Stephen 

Mr. Stephen R. Davis is President, Chief Executive Officer, Director of the Company. Mr. Davis brings over 20 years of executive-level experience in the pharmaceutical industry and more than 20 years of experience on the boards of directors of publicly held biopharmaceutical companies. He joined ACADIA in July 2014 as Executive Vice President, Chief Financial Officer and Chief Business Officer and was appointed Interim Chief Executive Officer in March 2015. Previously, Mr. Davis served as Executive Vice President and Chief Operating Officer at Heron Therapeutics, Inc., Executive Vice President and Chief Operating Officer at Ardea Biosciences, Inc., and in numerous executive roles at Neurogen Corporation, including Chief Executive Officer. Mr. Davis currently serves on the Board of Directors of Bellicum Pharmaceuticals, Inc. He also recently served on the Boards of directors of Synageva BioPharma Corp., Heron Therapeutics, and Furiex Pharmaceuticals, Inc. Early in his career, Mr. Davis practiced as a Certified Public Accountant with a major accounting firm and as a corporate and securities attorney with a Wall Street law firm. Mr. Davis received his Bachelor of Science degree in Accounting from Southern Nazarene University and a J.D. from Vanderbilt University.

Basic Compensation

Total Annual Compensation, USD 245,607
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 4,963,320
Fiscal Year Total, USD 5,208,920

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --